SCHEMBL6445905

SCHEMBL6445905

CCOC(=O)c1ccc(CF)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
ALDH1A1 P00352 11/20 0.57
KDM4E B2RXH2 5/20 0.57
MAPT P10636 4/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
POLB P06746 2/20 0.57
TLR2 O60603 1/20 0.57
NSD2 O96028 1/20 0.57
PKM P14618 1/20 0.57
MPI P34949 1/20 0.57
GRK6 P43250 1/20 0.57
RECQL P46063 1/20 0.57
TLR1 Q15399 1/20 0.57
TLR6 Q9Y2C9 1/20 0.57
LMNA P02545 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
GAA P10253 2/20 0.55
TSHR P16473 5/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL151035 0.89 ALDH1A1 (0.60) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL2093655 0.84 ALDH1A1 (0.58) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL6240522 0.84 ALDH1A1 (0.59) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL449698 0.83 HDAC4 (0.73) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL853606 0.83 ALDH1A1 (0.57) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL13064782 0.83 ALDH1A1 (0.60) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL852957 0.83 ALDH1A1 (0.58) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL2181967 0.83 ALDH1A1 (0.57) HDAC4HDAC6ALDH1A1KDM4EMAPT
SCHEMBL18263632 0.81 NPC1 (0.60) HDAC4HDAC6ALDH1A1KDM4EMAPT
Hydrochloric Acid SCHEMBL15823986 0.81 ALDH1A1 (0.57) HDAC4HDAC6ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 HDAC4 1236/4885HDAC6 1816/4885ALDH1A1 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.